FYB Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, asthma, hodgkin's lymphoma, urothelial carcinomas, tumors in the head and neck area, sinusitis with nasal polyps area, other tumor and genetic diseases; and FYB208 and FYB209 that is indicated for immunology areas. Formycon AG has cooperation agreements with Biocelys S.A. and Santo Biosimilar GmbH in connection with a biosimilar candidate. It has a collaboration with Biocelys S.A. to develop the biosimilar candidate FYB286. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.…
Industry Peers
BiotechnologyKey Statistics
About Formycon (ETR: FYB)
›
Formycon (ETR: FYB) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 196 employees.
The shares were at 14.00 EUR on 19 November 2026, down 39.8% over 52 weeks. Its 52-week range is 13.60 EUR to 26.95 EUR: the price is 48.1% below the high and 2.9% above the low.
Its market capitalisation is 247.42M EUR.
Formycon reports return on equity of -16.2%, an operating margin of -24.3% and revenue up 242.5% year over year.
It holds more cash than debt, a net cash position of 43.27M EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 40.17 EUR is 186.9% above the current price. The next earnings report is expected on 25 March 2027.